Haleon US Holdings LLC

Glenmark Receives US FDA Approval for Fluticasone Propionate Nasal Spray

- Glenmark Pharmaceuticals received U.S. FDA approval for Fluticasone Propionate Nasal Spray USP, 0.05 mg/spray (50 mcg/spray), expanding its respiratory portfolio in the U.S. market. - The product is bioequivalent and therapeutically equivalent to Flonase Nasal Spray, the reference listed drug marketed by Haleon US Holdings LLC. - According to IQVIA data for the 12 months ended June 2026, the Flonase Nasal Spray market recorded approximately US$295.2 million in annual sales. - The approval follows Glenmark's marketing nod for the OTC version of the drug in March, positioning fluticasone as a key U.S. sales driver.